KRAS Codons 12 and 13 Mutation Analysis : A Comparative Study between Direct Sequencing and a New Sensitive Real-Time PCR Assay

Abstract EN

KRAS somatic mutations are found in 30–40% of colorectal cancer (CRC).

Seven mutations in codons 12 and 13 of KRAS (95% of the observed human mutations) preclude the efficacy of anti-EGFR therapy for the treatment of CRC.

Assessment of KRAS mutational status has become a standard procedure in the management of patients with CRC.

Technically, KRAS mutation testing can be performed with different methods, characterized by distinct sensitivities and specificities.

The present study analyzed KRAS in 182 CRC histological samples by using direct sequencing and a new kit based on a Real-Time Sequence-Specific Primers-PCR technology.

The kit allowed to recover as positive 17 samples that were negative or unclear by sequencing, with a recovery rate equal to 13.82%.

This study proposes a fast, sensitive, and high-throughput system to identify such seven described mutations of KRAS gene in CRC samples.